Literature DB >> 14685029

Phenotype of peroxisome proliferator-activated receptor-alpha(PPARalpha)deficient mice on mixed background fed high fat diet.

Bang Hyun Kim1, Young Suk Won, Eun-Young Kim, Mijung Yoon, Ki-Taek Nam, Goo Taeg Oh, Dae-Yong Kim.   

Abstract

Considerable controversy exists in determining the role of peroxisome proliferator-activated receptor-alpha PPARalpha) on obesity. Previous reports demonstrated that PPARalpha is a critical modulator of lipid homeostasis, but the overt, obese phenotypic characterization in the strain of PPAR deficient (PPARalpha-/-) mice is influenced by other factors, including diet and genetics. Therefore, it is necessary to establish the phenotypic characterization of PPARalpha-/- mice prior to the obesity-related study. In this study, we observed phenotype of PPARalpha-/- mice on mixed genetic background (C57BL/6Nx129/Sv) fed a high fat diet for 16 weeks. PPARalpha-/- mice, regardless of sex, raised body growth rate significantly comparing with wild type and showed male-specific fatty change in the liver. They were shown to lack hepatic induction of PPARalpha target genes encoding enzymes for fatty acid beta-oxidation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14685029

Source DB:  PubMed          Journal:  J Vet Sci        ISSN: 1229-845X            Impact factor:   1.672


  9 in total

1.  Loss of hepatic PPARα promotes inflammation and serum hyperlipidemia in diet-induced obesity.

Authors:  David E Stec; Darren M Gordon; Jennifer A Hipp; Stephen Hong; Zachary L Mitchell; Natalia R Franco; J Walker Robison; Christopher D Anderson; Donald F Stec; Terry D Hinds
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2019-09-04       Impact factor: 3.619

2.  Gut commensal Bacteroides acidifaciens prevents obesity and improves insulin sensitivity in mice.

Authors:  J-Y Yang; Y-S Lee; Y Kim; S-H Lee; S Ryu; S Fukuda; K Hase; C-S Yang; H S Lim; M-S Kim; H-M Kim; S-H Ahn; B-E Kwon; H-J Ko; M-N Kweon
Journal:  Mucosal Immunol       Date:  2016-04-27       Impact factor: 7.313

3.  Role of Peroxisome Proliferator-Activated Receptor α in Diabetic Nephropathy.

Authors:  Sungjin Chung; Cheol Whee Park
Journal:  Diabetes Metab J       Date:  2011-08-31       Impact factor: 5.376

4.  Increased HO-1 levels ameliorate fatty liver development through a reduction of heme and recruitment of FGF21.

Authors:  Terry D Hinds; Komal Sodhi; Charles Meadows; Larisa Fedorova; Nitin Puri; Dong Hyun Kim; Stephen J Peterson; Joseph Shapiro; Nader G Abraham; Attallah Kappas
Journal:  Obesity (Silver Spring)       Date:  2013-12-02       Impact factor: 5.002

5.  RAP1 protects from obesity through its extratelomeric role regulating gene expression.

Authors:  Paula Martínez; Gonzalo Gómez-López; Fernando García; Evi Mercken; Sarah Mitchell; Juana M Flores; Rafael de Cabo; Maria A Blasco
Journal:  Cell Rep       Date:  2013-06-20       Impact factor: 9.423

6.  Adipose-Specific PPARα Knockout Mice Have Increased Lipogenesis by PASK-SREBP1 Signaling and a Polarity Shift to Inflammatory Macrophages in White Adipose Tissue.

Authors:  Terry D Hinds; Zachary A Kipp; Mei Xu; Frederique B Yiannikouris; Andrew J Morris; Donald F Stec; Walter Wahli; David E Stec
Journal:  Cells       Date:  2021-12-21       Impact factor: 6.600

Review 7.  Peroxisome proliferator-activated receptor targets for the treatment of metabolic diseases.

Authors:  Francisco A Monsalve; Radha D Pyarasani; Fernando Delgado-Lopez; Rodrigo Moore-Carrasco
Journal:  Mediators Inflamm       Date:  2013-05-27       Impact factor: 4.711

8.  Oea Signaling Pathways and the Metabolic Benefits of Vertical Sleeve Gastrectomy.

Authors:  Chelsea R Hutch; Danielle R Trakimas; Karen Roelofs; Joshua Pressler; Joyce Sorrell; Daniela Cota; Silvana Obici; Darleen A Sandoval
Journal:  Ann Surg       Date:  2020-03       Impact factor: 13.787

9.  Mice lacking RAP1 show early onset and higher rates of DEN-induced hepatocellular carcinomas in female mice.

Authors:  Iole Ferrara-Romeo; Paula Martínez; Maria A Blasco
Journal:  PLoS One       Date:  2018-10-11       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.